Domenico Tricarico, MSc Pharmacology, PhD

Printer-friendly versionPrinter-friendly version

Currently Associate prof. of Pharmacology & Toxicology, Dept of Pharmacobiology, Faculty of Pharmacy, Univ. of Bari, Italy

Education and training:

1987 Degree in Pharmacy, Univ. of Bari, Italy

1987−88 Fellow at laboratories of General Physiology, Univ. of ULM, Germany, directed by prof. R. Rüdel  sponsored by DGBM (Deutsche Gesellscahft Bekampfung der Muskelkrankheiten e.v.)

1988−91 Fellow at laboratories of Prof. D. Conte Camerino, Dept of Pharmacobiology, Faculty of Pharmacy, Univ. of Bari, Italy

1991−92 Fellow at laboratories of Prof. S.H.Bryant Dept. of Pharmacology and Cell Biophysic, College of Medicine, University of Cincinnati (OH), U.S.A.

1991−1993 PhD in Biochemistry and Cellular Pharmacology, Dept of Pharmacobiology, Faculty of Pharmacy, Univ. of Bari, Italy

Employment and research experience:
1995−2005 Researcher in Pharmacology, Faculty of Pharmacy, Univ. of Bari, Italy

1999 Visiting professor at laboratories of General Physiology, Univ. of ULM, Germany (prof. F. Lehmann−Horn)

1999−2008 prof. of Biology and Pharmacognosy, Course of Medicinal Chemistry, Faculty of Pharmacy, Univ. of Bari, Italy
2003−05 Prof. of Pharmacology, Course of Biotecnology, Univ. of Lecce, Italy

2005- Associate prof. of Pharmacology, Faculty of Pharmacy, Univ. of Bari, Italy

2005−11 prof. of Pharmacology and Toxicology, Course of Pharmacy, Faculty of Pharmacy, Univ. of Bari, Italy

2007−2011 Pharmacologist of the Ethical Comittee for the Clinical Investigations of the Azienda Ospedaliera Policlinico, Bari, Italy;
Consultant pharmacologist of the Ethical Comittee for the Clinical Investigations of the AUSL Lecce, Italy.

2007−2011 Clinical monitor for Azienda Ospedaliera Policlinico, Bari, Italy, in neurodegenerative disorders, psichiatry and oncology

Area of interest:
Ion channel biophysic and pharmacology
Neuromuscular disorders (Periodic Paralysis)
Insulin/glucose dismetabolisms
Clinical Pharmacology and Toxicology

Editorial activity
Associate editor of:  Frontiers in Pharmacology
Reviewer of:  Mol Pharmacol, J Apply Physiol, J Pharmacy and Pharmacology, J Pharmacology and Exp. Therapeutics
Autor and coautor of more than 45 peer review papers published on international journals, and more than 60 abstracts presented at meetings

Most recent peer−reviewed publications

1. Tricarico D and Conte Camerino D: Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. Frontiers in Pharmacology Review 2:1-8, 2011.
2. Tricarico D, Mele A, Camerino GM, Bottinelli R, Brocca L, Frigeri A, Svelto M, George A L Jr, Conte Camerino D: The KATP channel is a molecular sensor of atrophy in skeletal muscle. J Physiol 588: 773–784, 2010
3. Molecular determinants for the activating/blocking actions of the 2H−1,4−benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels. Tricarico D, Mele A, Camerino GM, Laghezza A, Carbonara G, Fracchiolla G, Tortorella P, Loiodice F, Camerino DC. Mol Pharmacol. 2008 Jul;74(1):50−8. Epub 2008 Apr 10.
4. Tricarico D, Lovaglio S, Mele A, Rotondo G, Mancinelli E, Meola G, Camerino DC.
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) −depleted rats.
Br J Pharmacol. 2008 May;154(1):183−90. Epub 2008 Mar 17.
5. Tricarico D, Mele A, Liss B, Ashcroft FM, Lundquist AL, Desai RR, George AL Jr, Conte Camerino D. Reduced expression of Kir6.2/SUR2A subunits explains KATP deficiency in K+−depleted rats. Neuromuscul Disord. 2008 Jan;18(1):74−80. Epub 2007 Sep 6.
6. Camerino DC, Desaphy JF, Tricarico D, Pierno S, Liantonio A.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19161833" Therapeutic approaches to ion channel diseases. Adv Genet. 2008;64:81-145. Review.

Publications related with periodic paralysis

1. Tricarico D, Mele A, Camerino GM, Laghezza A, Carbonara G, Fracchiolla G, Tortorella P, Loiodice F, Camerino DC. Molecular determinants for the activating/blocking actions of the 2H−1,4−benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels. Mol Pharmacol. 2008 Jul;74(1):50−8. Epub 2008 Apr 10.
2. Tricarico D, Mele A, Lundquist AL, Desai RR, George AL Jr, Conte Camerino D. Hybrid assemblies of ATP−sensitive K+ channels determine their muscle−type−dependent biophysical and pharmacological properties. Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1118−23. Epub 2006 Jan 17.
3. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+−deficient rats. FASEB J. 2004 Apr;18(6):760−1. Epub 2004 Feb 6.
4. Tricarico D, Barbieri M, Camerino DC. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol. 2000 Sep;48(3):304−12.
5. Tricarico D, Servidei S, Tonali P, Jurkat−Rott K, Camerino DC.  Impairment of skeletal muscle adenosine triphosphate−sensitive K+ channels in patients with hypokalemic periodic paralysis. J Clin Invest. 1999 Mar;103(5):675−82.